Damora Therapeutics (DMRA) Other Operating Expenses (2019 - 2025)
Damora Therapeutics' (DMRA) quarterly Other Operating Expenses came in at $174.3 million in Q4 2025, up 3866.1% YoY from $4.4 million in Q4 2024, and up 3866.1% on a QoQ basis from $4.4 million in Q4 2024.
Damora Therapeutics (DMRA) Other Operating Expenses (2019 - 2025) Analysis & Trends
Damora Therapeutics (DMRA) has 4 years of Other Operating Expenses data on file, last reported at $174.3 million in Q4 2025.
- Quarterly Other Operating Expenses rose 3866.1% year-over-year to $174.3 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $174.3 million (up 3150.23% YoY) and the FY2025 annual result came in at $174.3 million, up 3150.23% from the prior year.
- Other Operating Expenses improved to $174.3 million in Q4 2025, from $4.4 million in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of $174.3 million in Q4 2025 to a low of $720000.0 in Q4 2023.
- A 3-year average of $36.6 million and a median of $2.7 million in 2023 frame the typical range for Other Operating Expenses.
- Annual changes were most pronounced in 2024 — Other Operating Expenses jumped 510.42% — and 2025, when it surged 3866.1%.
- Tracing DMRA's Other Operating Expenses over 3 years: stood at $720000.0 in 2023, then jumped by 510.42% to $4.4 million in 2024, then surged by 3866.1% to $174.3 million in 2025.
- The last three Other Operating Expenses figures came in at $174.3 million (Q4 2025), $4.4 million (Q4 2024), and $968000.0 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Damora Therapeutics | 1.92 Bn | 1.38 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 174.31 Mn |
| Dec 31, 2024 | 4.40 Mn |
| Jun 30, 2024 | 968,000.00 |
| Dec 31, 2023 | 720,000.00 |
| Sep 30, 2023 | 2.73 Mn |
| Dec 31, 2019 | 16.79 Mn |